Therefore, our present results should provide us with a novel concept that the expansion of effector T cells derived from TRM in tumor sites was important for the success in tumor immunotherapies and that the helper peptide vaccine played an essential role in this step through the induction of the antigen-specific helper CD4+ T cells in the vicinity of TRM. This evidence concerns the gene CD4 and neoplasm.